YTS102 / BriSTAR Immunotech - LARVOL DELTA

Iterative engineering of GPC-3 targeted synthetic TCR and antigen receptor (STAR) cells in advanced solid tumors (AACR 2026) - P1 | "We further optimized the construct to enhance T-cell expansion and persistence, leading to a v3 version armored with membrane-bound IL-15 (mbIL-15). The STAR-T platform utilizes a high-affinity GPC3-specific scFv (GC33) fused to TCR constant domains... Iterative engineering of GPC3-targeted STAR-T cells with functionalities to enhance tumor trafficking (CXCR2) and persistence (mbIL-15) results in potent anti-tumor activity. Early clinical data demonstrate a favorable safety profile and promising efficacy in heavily pretreated patients with GPC3-positive solid tumors. These findings validate our optimization strategy and support the continued clinical development of YTS102 as a promising therapeutic for solid tumors."

First-in-human • Metastases • Gastric Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • CXCR2 • GPC3 • IL15

GPC3-CAR-T Cells for the Hepatocellular Carcinoma (clinicaltrials.gov) - P1 | N=12 | Suspended | Sponsor: Beijing Tsinghua Chang Gung Hospital | Not yet recruiting ➔ Suspended

CAR T-Cell Therapy • Trial suspension • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

GPC3-CAR-T Cells for the Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Beijing Tsinghua Chang Gung Hospital; Trial completion date: Nov 2022 ➔ Oct 2023; Initiation date: Aug 2020 ➔ Sep 2021; Trial primary completion date: Aug 2022 ➔ Jun 2023

Clinical • Trial completion date • Trial initiation date • Trial primary completion date • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor • GPC3

GPC3-CAR-T Cells for the Hepatocellular Carcinoma (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Beijing Tsinghua Chang Gung Hospital

Clinical • New P1 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor